nodes	percent_of_prediction	percent_of_DWPC	metapath
Dimetindene—Nortriptyline—ADRA1D—polycystic ovary syndrome	0.0113	0.0848	CrCbGaD
Dimetindene—Doxepin—ADRA1D—polycystic ovary syndrome	0.0102	0.0761	CrCbGaD
Dimetindene—Nortriptyline—ADRA1B—polycystic ovary syndrome	0.00967	0.0724	CrCbGaD
Dimetindene—Trimipramine—ADRA1B—polycystic ovary syndrome	0.0091	0.0682	CrCbGaD
Dimetindene—Promazine—ADRA1D—polycystic ovary syndrome	0.00904	0.0677	CrCbGaD
Dimetindene—Doxepin—ADRA1B—polycystic ovary syndrome	0.00867	0.065	CrCbGaD
Dimetindene—Imipramine—ADRA1D—polycystic ovary syndrome	0.00791	0.0592	CrCbGaD
Dimetindene—Amitriptyline—ADRA1D—polycystic ovary syndrome	0.00786	0.0589	CrCbGaD
Dimetindene—Promazine—ADRA1B—polycystic ovary syndrome	0.00771	0.0577	CrCbGaD
Dimetindene—Imipramine—ADRA1B—polycystic ovary syndrome	0.00675	0.0505	CrCbGaD
Dimetindene—Amitriptyline—ADRA1B—polycystic ovary syndrome	0.00671	0.0502	CrCbGaD
Dimetindene—Nortriptyline—ADRA1A—polycystic ovary syndrome	0.00651	0.0487	CrCbGaD
Dimetindene—Trimipramine—ADRA1A—polycystic ovary syndrome	0.00613	0.0459	CrCbGaD
Dimetindene—Promethazine—ADRA1A—polycystic ovary syndrome	0.0059	0.0442	CrCbGaD
Dimetindene—Doxepin—ADRA1A—polycystic ovary syndrome	0.00584	0.0437	CrCbGaD
Dimetindene—Promazine—ADRA1A—polycystic ovary syndrome	0.00519	0.0389	CrCbGaD
Dimetindene—Imipramine—ADRA1A—polycystic ovary syndrome	0.00454	0.034	CrCbGaD
Dimetindene—Amitriptyline—ADRA1A—polycystic ovary syndrome	0.00452	0.0338	CrCbGaD
Dimetindene—CHRM2—GPCR ligand binding—PTGER3—polycystic ovary syndrome	0.00303	0.0035	CbGpPWpGaD
Dimetindene—CHRM2—GPCR ligand binding—LHCGR—polycystic ovary syndrome	0.00303	0.0035	CbGpPWpGaD
Dimetindene—CHRM2—GPCRs, Class A Rhodopsin-like—ADRB3—polycystic ovary syndrome	0.00299	0.00346	CbGpPWpGaD
Dimetindene—HRH1—Class A/1 (Rhodopsin-like receptors)—FSHR—polycystic ovary syndrome	0.00296	0.00342	CbGpPWpGaD
Dimetindene—CHRM2—Class A/1 (Rhodopsin-like receptors)—FSHR—polycystic ovary syndrome	0.00291	0.00336	CbGpPWpGaD
Dimetindene—HRH1—GPCR ligand binding—PTAFR—polycystic ovary syndrome	0.00288	0.00333	CbGpPWpGaD
Dimetindene—CHRM2—G alpha (i) signalling events—MTNR1B—polycystic ovary syndrome	0.00285	0.00329	CbGpPWpGaD
Dimetindene—CHRM2—GPCR ligand binding—PTAFR—polycystic ovary syndrome	0.00284	0.00327	CbGpPWpGaD
Dimetindene—HRH1—GPCR ligand binding—ADRA1D—polycystic ovary syndrome	0.0028	0.00323	CbGpPWpGaD
Dimetindene—CHRM2—GPCR ligand binding—ADRA1D—polycystic ovary syndrome	0.00275	0.00318	CbGpPWpGaD
Dimetindene—CHRM2—SIDS Susceptibility Pathways—TH—polycystic ovary syndrome	0.00275	0.00317	CbGpPWpGaD
Dimetindene—HRH1—GPCR ligand binding—ADRA1B—polycystic ovary syndrome	0.00272	0.00314	CbGpPWpGaD
Dimetindene—HRH1—Class A/1 (Rhodopsin-like receptors)—ADRA1A—polycystic ovary syndrome	0.00271	0.00313	CbGpPWpGaD
Dimetindene—HRH1—GPCRs, Class A Rhodopsin-like—MTNR1B—polycystic ovary syndrome	0.00269	0.0031	CbGpPWpGaD
Dimetindene—CHRM2—GPCR ligand binding—ADRA1B—polycystic ovary syndrome	0.00268	0.00309	CbGpPWpGaD
Dimetindene—CHRM2—Class A/1 (Rhodopsin-like receptors)—ADRA1A—polycystic ovary syndrome	0.00266	0.00308	CbGpPWpGaD
Dimetindene—CHRM2—GPCRs, Class A Rhodopsin-like—MTNR1B—polycystic ovary syndrome	0.00264	0.00305	CbGpPWpGaD
Dimetindene—HRH1—Class A/1 (Rhodopsin-like receptors)—ADRB3—polycystic ovary syndrome	0.00261	0.00301	CbGpPWpGaD
Dimetindene—HRH1—Class A/1 (Rhodopsin-like receptors)—LHB—polycystic ovary syndrome	0.00258	0.00297	CbGpPWpGaD
Dimetindene—HRH1—G alpha (q) signalling events—GHRL—polycystic ovary syndrome	0.00257	0.00296	CbGpPWpGaD
Dimetindene—CHRM2—Class A/1 (Rhodopsin-like receptors)—ADRB3—polycystic ovary syndrome	0.00256	0.00296	CbGpPWpGaD
Dimetindene—CHRM2—Class A/1 (Rhodopsin-like receptors)—LHB—polycystic ovary syndrome	0.00253	0.00293	CbGpPWpGaD
Dimetindene—HRH1—Class A/1 (Rhodopsin-like receptors)—GNRH1—polycystic ovary syndrome	0.00252	0.00291	CbGpPWpGaD
Dimetindene—CHRM2—Calcium Regulation in the Cardiac Cell—ADRB2—polycystic ovary syndrome	0.00251	0.00289	CbGpPWpGaD
Dimetindene—CHRM2—Class A/1 (Rhodopsin-like receptors)—GNRH1—polycystic ovary syndrome	0.00248	0.00286	CbGpPWpGaD
Dimetindene—CHRM2—SIDS Susceptibility Pathways—AR—polycystic ovary syndrome	0.00244	0.00282	CbGpPWpGaD
Dimetindene—CHRM2—Calcium Regulation in the Cardiac Cell—GNAS—polycystic ovary syndrome	0.00233	0.00268	CbGpPWpGaD
Dimetindene—HRH1—Class A/1 (Rhodopsin-like receptors)—MTNR1B—polycystic ovary syndrome	0.0023	0.00266	CbGpPWpGaD
Dimetindene—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—GHRL—polycystic ovary syndrome	0.0023	0.00265	CbGpPWpGaD
Dimetindene—CHRM2—Class A/1 (Rhodopsin-like receptors)—MTNR1B—polycystic ovary syndrome	0.00227	0.00261	CbGpPWpGaD
Dimetindene—HRH1—GPCR ligand binding—FSHR—polycystic ovary syndrome	0.00225	0.0026	CbGpPWpGaD
Dimetindene—CHRM2—GPCR ligand binding—FSHR—polycystic ovary syndrome	0.00222	0.00256	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—NPB—polycystic ovary syndrome	0.00209	0.00241	CbGpPWpGaD
Dimetindene—HRH1—GPCR ligand binding—ADRA1A—polycystic ovary syndrome	0.00206	0.00238	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—NPB—polycystic ovary syndrome	0.00205	0.00237	CbGpPWpGaD
Dimetindene—CHRM2—GPCR ligand binding—ADRA1A—polycystic ovary syndrome	0.00203	0.00234	CbGpPWpGaD
Dimetindene—HRH1—GPCR ligand binding—ADRB3—polycystic ovary syndrome	0.00199	0.00229	CbGpPWpGaD
Dimetindene—CHRM2—SIDS Susceptibility Pathways—NR3C1—polycystic ovary syndrome	0.00198	0.00228	CbGpPWpGaD
Dimetindene—HRH1—GPCR ligand binding—LHB—polycystic ovary syndrome	0.00196	0.00226	CbGpPWpGaD
Dimetindene—CHRM2—GPCR ligand binding—ADRB3—polycystic ovary syndrome	0.00195	0.00225	CbGpPWpGaD
Dimetindene—CHRM2—GPCR ligand binding—LHB—polycystic ovary syndrome	0.00193	0.00223	CbGpPWpGaD
Dimetindene—HRH1—GPCR ligand binding—GNRH1—polycystic ovary syndrome	0.00192	0.00221	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—NPB—polycystic ovary syndrome	0.00189	0.00219	CbGpPWpGaD
Dimetindene—CHRM2—GPCR ligand binding—GNRH1—polycystic ovary syndrome	0.00189	0.00218	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—PLEKHG5—polycystic ovary syndrome	0.00189	0.00218	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—NPB—polycystic ovary syndrome	0.00186	0.00215	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—PLEKHG5—polycystic ovary syndrome	0.00186	0.00214	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—ARHGAP23—polycystic ovary syndrome	0.00185	0.00213	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—ARHGAP30—polycystic ovary syndrome	0.00185	0.00213	CbGpPWpGaD
Dimetindene—HRH1—GPCR ligand binding—SCT—polycystic ovary syndrome	0.00184	0.00212	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—ARHGAP23—polycystic ovary syndrome	0.00182	0.0021	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—ARHGAP30—polycystic ovary syndrome	0.00182	0.0021	CbGpPWpGaD
Dimetindene—CHRM2—GPCR ligand binding—SCT—polycystic ovary syndrome	0.00181	0.00209	CbGpPWpGaD
Dimetindene—KCNH2—SIDS Susceptibility Pathways—VEGFA—polycystic ovary syndrome	0.00178	0.00206	CbGpPWpGaD
Dimetindene—HRH1—GPCR ligand binding—MTNR1B—polycystic ovary syndrome	0.00175	0.00202	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—LHCGR—polycystic ovary syndrome	0.00174	0.00201	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—PTGER3—polycystic ovary syndrome	0.00174	0.00201	CbGpPWpGaD
Dimetindene—CHRM2—GPCR ligand binding—MTNR1B—polycystic ovary syndrome	0.00173	0.00199	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—PLEKHG5—polycystic ovary syndrome	0.00171	0.00198	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—PTGER3—polycystic ovary syndrome	0.00171	0.00198	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—LHCGR—polycystic ovary syndrome	0.00171	0.00198	CbGpPWpGaD
Dimetindene—HRH1—Class A/1 (Rhodopsin-like receptors)—GHRL—polycystic ovary syndrome	0.0017	0.00196	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—PLEKHG5—polycystic ovary syndrome	0.00169	0.00195	CbGpPWpGaD
Dimetindene—CHRM2—Class A/1 (Rhodopsin-like receptors)—GHRL—polycystic ovary syndrome	0.00167	0.00193	CbGpPWpGaD
Dimetindene—HRH1—GPCRs, Class A Rhodopsin-like—ADRB2—polycystic ovary syndrome	0.00164	0.0019	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—PTAFR—polycystic ovary syndrome	0.00163	0.00188	CbGpPWpGaD
Dimetindene—CHRM2—GPCRs, Class A Rhodopsin-like—ADRB2—polycystic ovary syndrome	0.00162	0.00187	CbGpPWpGaD
Dimetindene—CHRM2—G alpha (i) signalling events—GNAS—polycystic ovary syndrome	0.00162	0.00186	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—PTAFR—polycystic ovary syndrome	0.0016	0.00185	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—PTGER3—polycystic ovary syndrome	0.00158	0.00182	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—LHCGR—polycystic ovary syndrome	0.00158	0.00182	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—ADRA1D—polycystic ovary syndrome	0.00158	0.00182	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—PTGER3—polycystic ovary syndrome	0.00156	0.0018	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—LHCGR—polycystic ovary syndrome	0.00156	0.0018	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—ADRA1D—polycystic ovary syndrome	0.00156	0.0018	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—ADRA1B—polycystic ovary syndrome	0.00154	0.00177	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—ADRA1B—polycystic ovary syndrome	0.00151	0.00175	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—PTAFR—polycystic ovary syndrome	0.00148	0.00171	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—PTAFR—polycystic ovary syndrome	0.00145	0.00168	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—ADRA1D—polycystic ovary syndrome	0.00144	0.00166	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—ADRA1D—polycystic ovary syndrome	0.00141	0.00163	CbGpPWpGaD
Dimetindene—HRH1—Class A/1 (Rhodopsin-like receptors)—ADRB2—polycystic ovary syndrome	0.00141	0.00162	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—PDE3B—polycystic ovary syndrome	0.0014	0.00161	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—ADRA1B—polycystic ovary syndrome	0.0014	0.00161	CbGpPWpGaD
Dimetindene—CHRM2—Class A/1 (Rhodopsin-like receptors)—ADRB2—polycystic ovary syndrome	0.00139	0.0016	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—PDE3B—polycystic ovary syndrome	0.00138	0.00159	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—ADRA1B—polycystic ovary syndrome	0.00137	0.00159	CbGpPWpGaD
Dimetindene—HRH1—GPCR ligand binding—GHRL—polycystic ovary syndrome	0.00129	0.00149	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—FLT4—polycystic ovary syndrome	0.00128	0.00148	CbGpPWpGaD
Dimetindene—CHRM2—GPCR ligand binding—GHRL—polycystic ovary syndrome	0.00127	0.00147	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—FSHR—polycystic ovary syndrome	0.00127	0.00147	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—PDE3B—polycystic ovary syndrome	0.00127	0.00147	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—FLT4—polycystic ovary syndrome	0.00126	0.00145	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—FSHR—polycystic ovary syndrome	0.00125	0.00145	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—PDE3B—polycystic ovary syndrome	0.00125	0.00144	CbGpPWpGaD
Dimetindene—KCNH2—SIDS Susceptibility Pathways—IL6—polycystic ovary syndrome	0.00123	0.00142	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—ADRA1A—polycystic ovary syndrome	0.00117	0.00134	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—FSHR—polycystic ovary syndrome	0.00116	0.00134	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—ADRA1A—polycystic ovary syndrome	0.00115	0.00132	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—FSHR—polycystic ovary syndrome	0.00114	0.00131	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—ADRB3—polycystic ovary syndrome	0.00112	0.00129	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—NPB—polycystic ovary syndrome	0.00112	0.00129	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—LHB—polycystic ovary syndrome	0.00111	0.00128	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—ADRB3—polycystic ovary syndrome	0.0011	0.00127	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—NPB—polycystic ovary syndrome	0.0011	0.00127	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—LHB—polycystic ovary syndrome	0.00109	0.00126	CbGpPWpGaD
Dimetindene—CHRM2—G alpha (i) signalling events—POMC—polycystic ovary syndrome	0.00109	0.00126	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	0.00108	0.00125	CbGpPWpGaD
Dimetindene—HRH1—GPCR ligand binding—ADRB2—polycystic ovary syndrome	0.00107	0.00124	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	0.00107	0.00123	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	0.00106	0.00122	CbGpPWpGaD
Dimetindene—CHRM2—GPCR ligand binding—ADRB2—polycystic ovary syndrome	0.00105	0.00122	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	0.00104	0.0012	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—SCT—polycystic ovary syndrome	0.00104	0.0012	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—SCT—polycystic ovary syndrome	0.00102	0.00118	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—ADRB3—polycystic ovary syndrome	0.00102	0.00118	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	0.00101	0.00117	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—LHB—polycystic ovary syndrome	0.00101	0.00116	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—ADRB3—polycystic ovary syndrome	0.001	0.00116	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	0.000996	0.00115	CbGpPWpGaD
Dimetindene—HRH1—GPCR ligand binding—GNAS—polycystic ovary syndrome	0.000994	0.00115	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	0.000991	0.00114	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—LHB—polycystic ovary syndrome	0.00099	0.00114	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—GNRH1—polycystic ovary syndrome	0.000984	0.00114	CbGpPWpGaD
Dimetindene—CHRM2—GPCR ligand binding—GNAS—polycystic ovary syndrome	0.000978	0.00113	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	0.000975	0.00113	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—GNRH1—polycystic ovary syndrome	0.000968	0.00112	CbGpPWpGaD
Dimetindene—CHRM2—SIDS Susceptibility Pathways—VEGFA—polycystic ovary syndrome	0.000948	0.00109	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—SCT—polycystic ovary syndrome	0.000943	0.00109	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—LHCGR—polycystic ovary syndrome	0.000934	0.00108	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—PTGER3—polycystic ovary syndrome	0.000934	0.00108	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—SCT—polycystic ovary syndrome	0.000928	0.00107	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—LHCGR—polycystic ovary syndrome	0.000919	0.00106	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—PTGER3—polycystic ovary syndrome	0.000919	0.00106	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	0.0009	0.00104	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	0.000885	0.00102	CbGpPWpGaD
Dimetindene—HRH1—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	0.000879	0.00101	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—PTAFR—polycystic ovary syndrome	0.000873	0.00101	CbGpPWpGaD
Dimetindene—CHRM2—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	0.000865	0.000998	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—PTAFR—polycystic ovary syndrome	0.000859	0.000992	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—ADRA1D—polycystic ovary syndrome	0.000848	0.000979	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—ADRA1D—polycystic ovary syndrome	0.000834	0.000963	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—ADRA1B—polycystic ovary syndrome	0.000825	0.000952	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—ADRA1B—polycystic ovary syndrome	0.000812	0.000937	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—INHBB—polycystic ovary syndrome	0.000804	0.000928	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—INHBB—polycystic ovary syndrome	0.000791	0.000913	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—PDE3B—polycystic ovary syndrome	0.00075	0.000866	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—PDE3B—polycystic ovary syndrome	0.000738	0.000852	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—GHRL—polycystic ovary syndrome	0.000732	0.000845	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—GHRL—polycystic ovary syndrome	0.00072	0.000831	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—FSHR—polycystic ovary syndrome	0.000684	0.000789	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—FSHR—polycystic ovary syndrome	0.000673	0.000776	CbGpPWpGaD
Dimetindene—HRH1—GPCR ligand binding—POMC—polycystic ovary syndrome	0.000669	0.000772	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—GHRL—polycystic ovary syndrome	0.000665	0.000767	CbGpPWpGaD
Dimetindene—CHRM2—GPCR ligand binding—POMC—polycystic ovary syndrome	0.000659	0.00076	CbGpPWpGaD
Dimetindene—CHRM2—SIDS Susceptibility Pathways—IL6—polycystic ovary syndrome	0.000656	0.000757	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—GHRL—polycystic ovary syndrome	0.000654	0.000755	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.000643	0.000742	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.000632	0.00073	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.000625	0.000722	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.000615	0.00071	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—FST—polycystic ovary syndrome	0.000609	0.000703	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	0.000606	0.000699	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.000602	0.000695	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—FST—polycystic ovary syndrome	0.000599	0.000692	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	0.000596	0.000688	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—LHB—polycystic ovary syndrome	0.000595	0.000686	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.000592	0.000683	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—LHB—polycystic ovary syndrome	0.000585	0.000675	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.000581	0.000671	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.000572	0.00066	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.000563	0.00065	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—GNAS—polycystic ovary syndrome	0.000562	0.000648	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—SCT—polycystic ovary syndrome	0.000557	0.000643	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.000554	0.000639	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—GNAS—polycystic ovary syndrome	0.000553	0.000638	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—ADRB2—polycystic ovary syndrome	0.00055	0.000635	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—SCT—polycystic ovary syndrome	0.000548	0.000633	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—ADRB2—polycystic ovary syndrome	0.000541	0.000625	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.000532	0.000613	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.000523	0.000604	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000522	0.000603	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—RBP4—polycystic ovary syndrome	0.000518	0.000598	CbGpPWpGaD
Dimetindene—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	0.000516	0.000595	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000514	0.000593	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.00051	0.000589	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—RBP4—polycystic ovary syndrome	0.00051	0.000588	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.000502	0.000579	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—YAP1—polycystic ovary syndrome	0.000484	0.000558	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—GAB1—polycystic ovary syndrome	0.000477	0.00055	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—YAP1—polycystic ovary syndrome	0.000476	0.000549	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—GAB1—polycystic ovary syndrome	0.000469	0.000542	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—INSR—polycystic ovary syndrome	0.000456	0.000526	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—INSR—polycystic ovary syndrome	0.000449	0.000518	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.000433	0.0005	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.000427	0.000492	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.000426	0.000492	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—PGR—polycystic ovary syndrome	0.000422	0.000487	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.00042	0.000484	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—PGR—polycystic ovary syndrome	0.000416	0.00048	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—GHRL—polycystic ovary syndrome	0.000393	0.000453	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—PLAT—polycystic ovary syndrome	0.000393	0.000453	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—PLAT—polycystic ovary syndrome	0.000386	0.000446	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—GHRL—polycystic ovary syndrome	0.000386	0.000446	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—POMC—polycystic ovary syndrome	0.000378	0.000436	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—ATF1—polycystic ovary syndrome	0.000375	0.000432	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—POMC—polycystic ovary syndrome	0.000372	0.000429	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—ATF1—polycystic ovary syndrome	0.000369	0.000425	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.000365	0.000422	CbGpPWpGaD
Dimetindene—HRH1—GPCR downstream signaling—AKT2—polycystic ovary syndrome	0.000364	0.00042	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.000359	0.000415	CbGpPWpGaD
Dimetindene—CHRM2—GPCR downstream signaling—AKT2—polycystic ovary syndrome	0.000358	0.000413	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—NGFR—polycystic ovary syndrome	0.000346	0.000399	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—POMC—polycystic ovary syndrome	0.000343	0.000396	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—PRL—polycystic ovary syndrome	0.000343	0.000395	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—NGFR—polycystic ovary syndrome	0.00034	0.000393	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—POMC—polycystic ovary syndrome	0.000338	0.00039	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—PRL—polycystic ovary syndrome	0.000337	0.000389	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—AKT2—polycystic ovary syndrome	0.00033	0.000381	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—ADRB2—polycystic ovary syndrome	0.000325	0.000375	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—AKT2—polycystic ovary syndrome	0.000325	0.000375	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—ADRB2—polycystic ovary syndrome	0.00032	0.000369	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—GNAS—polycystic ovary syndrome	0.000301	0.000348	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—GNAS—polycystic ovary syndrome	0.000296	0.000342	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—NCOR1—polycystic ovary syndrome	0.000287	0.000331	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—NCOR1—polycystic ovary syndrome	0.000282	0.000326	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—NRG1—polycystic ovary syndrome	0.000282	0.000325	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—NRG1—polycystic ovary syndrome	0.000277	0.00032	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—IRS2—polycystic ovary syndrome	0.000241	0.000279	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—IRS2—polycystic ovary syndrome	0.000237	0.000274	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—LEP—polycystic ovary syndrome	0.000236	0.000273	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—LEP—polycystic ovary syndrome	0.000232	0.000268	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—IRS1—polycystic ovary syndrome	0.000211	0.000243	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—IRS1—polycystic ovary syndrome	0.000207	0.000239	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—POMC—polycystic ovary syndrome	0.000203	0.000234	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—INS—polycystic ovary syndrome	0.000202	0.000233	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—POMC—polycystic ovary syndrome	0.0002	0.00023	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—INS—polycystic ovary syndrome	0.000199	0.000229	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—IGF1—polycystic ovary syndrome	0.000195	0.000225	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—AKT2—polycystic ovary syndrome	0.000195	0.000225	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—IGF1—polycystic ovary syndrome	0.000192	0.000222	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—AKT2—polycystic ovary syndrome	0.000192	0.000221	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	0.000185	0.000214	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	0.000182	0.00021	CbGpPWpGaD
Dimetindene—HRH1—Signaling by GPCR—IL6—polycystic ovary syndrome	0.000149	0.000172	CbGpPWpGaD
Dimetindene—CHRM2—Signaling by GPCR—IL6—polycystic ovary syndrome	0.000147	0.000169	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—VEGFA—polycystic ovary syndrome	0.000127	0.000147	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—VEGFA—polycystic ovary syndrome	0.000125	0.000145	CbGpPWpGaD
Dimetindene—HRH1—Signaling Pathways—IL6—polycystic ovary syndrome	8.82e-05	0.000102	CbGpPWpGaD
Dimetindene—CHRM2—Signaling Pathways—IL6—polycystic ovary syndrome	8.67e-05	0.0001	CbGpPWpGaD
